2022
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials
Behnoush A, Yazdani K, Khalaji A, Tavolinejad H, Aminorroaya A, Jalali A, Tajdini M. Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials. Heart Rhythm 2022, 20: 448-460. PMID: 36509319, DOI: 10.1016/j.hrthm.2022.12.010.Peer-Reviewed Original ResearchConceptsHead-up tilt testPositive head-up tilt testNetwork meta-analysisRandomized controlled trialsVasovagal syncopeMeta-analysisPharmacological therapyPrimary outcomeRisk ratioRandom-effects network meta-analysisSystematic reviewPooled risk ratioConfidence intervalsHealth care systemLevel of evidenceCumulative ranking curve analysisPairwise meta-analysisTreatment optionsWeb of ScienceSyncopal eventsTilt testCare systemComparative efficacySecondary outcomesCochrane Library
2020
Comparison of trinitroglycerin and adenosine as provocative agents for head-up tilt test in patients with unexplained syncope: a semi-crossover randomized clinical trial with prospective follow-up
Tajdini M, Aminorroaya A, Rahimi B, Mortazavi S, Vasheghani Farahani A, Sadeghian S, Easapour Moghadam M, Soltani D, Bozorgi A. Comparison of trinitroglycerin and adenosine as provocative agents for head-up tilt test in patients with unexplained syncope: a semi-crossover randomized clinical trial with prospective follow-up. Journal Of Interventional Cardiac Electrophysiology 2020, 60: 31-39. PMID: 31907833, DOI: 10.1007/s10840-019-00652-6.Peer-Reviewed Original ResearchConceptsTransient loss of consciousnessFollow-upUnexplained syncopeProvocative agentsTilt testDiagnostic evaluationPositive response to HUTTHead-up tilt testResponse to HUTTSuspected vasovagal syncopeRandomized clinical trialsDiagnosis of unexplained syncopeStatistically significant differenceDiagnostic yieldLoss of consciousnessRandomized patientsEvaluating patientsVasovagal syncopeVasovagal responseClinical trialsIntravenous ADPatientsSyncopeTrinitroglycerinRe-admission